Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry Rabbitts

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature Communications|June 28, 2020
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRASNicolas Bery, Ami Miller, Terry Rabbitts
Mabs|April 23, 2020
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formatsAmi Miller, Stephen Carr, Terry Rabbitts, et al.
Scientific Reports|January 19, 2021
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibodyTomoyuki Tanaka, Jemima Thomas, Rob Van Montfort, et al.
Journal of Immunological Methods|April 1, 2021
Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compoundsPeter Canning, Carole Bataille, Nicolas Bery, et al.
Experimental Hematology|May 22, 2020
Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocationRoshani Sinha, Cristina Porcheri, Teresa d'Altri, et al.
Iscience|April 19, 2024
Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1Daniel J L Coleman, Peter Keane, Paulynn S Chin, et al.
British Journal of Cancer|June 13, 2026
Paediatric Therapeutic Development Workshop on rhabdomyosarcomaJoseph S Baxter, Claudia Montiel Equihua, Jan J Molenaar, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature Communications|June 28, 2020
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRASNicolas Bery, Ami Miller, Terry Rabbitts
Mabs|April 23, 2020
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formatsAmi Miller, Stephen Carr, Terry Rabbitts, et al.
Scientific Reports|January 19, 2021
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibodyTomoyuki Tanaka, Jemima Thomas, Rob Van Montfort, et al.
Journal of Immunological Methods|April 1, 2021
Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compoundsPeter Canning, Carole Bataille, Nicolas Bery, et al.
Experimental Hematology|May 22, 2020
Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocationRoshani Sinha, Cristina Porcheri, Teresa d'Altri, et al.
Iscience|April 19, 2024
Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1Daniel J L Coleman, Peter Keane, Paulynn S Chin, et al.
British Journal of Cancer|June 13, 2026
Paediatric Therapeutic Development Workshop on rhabdomyosarcomaJoseph S Baxter, Claudia Montiel Equihua, Jan J Molenaar, et al.
Pageof 1